A 52-week, double-blind, randomised, placebo-controlled, parallel-group phase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D)

Trial Profile

A 52-week, double-blind, randomised, placebo-controlled, parallel-group phase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in female patients with irritable bowel syndrome with diarrhoea (IBS-D)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Ibodutant (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms IRIS-4
  • Sponsors Menarini Ricerche
  • Most Recent Events

    • 17 Mar 2017 This trial has been completed in United Kingdom (end date: 3 Nov 2015).
    • 18 May 2016 Status changed from active, no longer recruiting to discontinued.
    • 08 Apr 2015 Planned End Date changed from 1 Apr 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top